Qingdao Vland Biotech Co Ltd (603739) - Net Assets
Based on the latest financial reports, Qingdao Vland Biotech Co Ltd (603739) has net assets worth CN¥1.90 Billion CNY (≈ $278.21 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.04 Billion ≈ $445.07 Million USD) and total liabilities (CN¥1.14 Billion ≈ $166.87 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Qingdao Vland Biotech Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.90 Billion |
| % of Total Assets | 62.51% |
| Annual Growth Rate | 14.9% |
| 5-Year Change | 67.68% |
| 10-Year Change | 260.06% |
| Growth Volatility | 20.74 |
Qingdao Vland Biotech Co Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Qingdao Vland Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Qingdao Vland Biotech Co Ltd (603739) total assets for the complete picture of this company's asset base.
Annual Net Assets for Qingdao Vland Biotech Co Ltd (2014–2024)
The table below shows the annual net assets of Qingdao Vland Biotech Co Ltd from 2014 to 2024. For live valuation and market cap data, see Qingdao Vland Biotech Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.87 Billion ≈ $273.64 Million |
+2.44% |
| 2023-12-31 | CN¥1.83 Billion ≈ $267.11 Million |
+5.28% |
| 2022-12-31 | CN¥1.73 Billion ≈ $253.73 Million |
+2.87% |
| 2021-12-31 | CN¥1.69 Billion ≈ $246.65 Million |
+51.14% |
| 2020-12-31 | CN¥1.12 Billion ≈ $163.20 Million |
+8.04% |
| 2019-12-31 | CN¥1.03 Billion ≈ $151.05 Million |
+63.49% |
| 2018-12-31 | CN¥631.38 Million ≈ $92.39 Million |
+6.56% |
| 2017-12-31 | CN¥592.53 Million ≈ $86.71 Million |
+6.19% |
| 2016-12-31 | CN¥557.97 Million ≈ $81.65 Million |
+7.43% |
| 2015-12-31 | CN¥519.36 Million ≈ $76.00 Million |
+11.39% |
| 2014-12-31 | CN¥466.26 Million ≈ $68.23 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Qingdao Vland Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 141.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥740.81 Million | 42.63% |
| Common Stock | CN¥253.03 Million | 14.56% |
| Other Components | CN¥743.88 Million | 42.81% |
| Total Equity | CN¥1.74 Billion | 100.00% |
Qingdao Vland Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Qingdao Vland Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SNT Motiv Co Ltd
KO:064960
|
$557.25 Million |
|
Pubang Landscape Architecture Co Ltd
SHE:002663
|
$557.32 Million |
|
GR Engineering Services Ltd
AU:GNG
|
$557.44 Million |
|
Zhengzhou Tiamaes Technology Co Ltd
SHE:300807
|
$557.75 Million |
|
Canadian Tire Corporation Limited
TO:CTC
|
$557.19 Million |
|
CJ CGV
KO:079160
|
$557.13 Million |
|
MiCo Ltd
KQ:059090
|
$557.09 Million |
|
Pagerduty Inc
NYSE:PD
|
$557.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Qingdao Vland Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,708,293,232 to 1,737,720,580, a change of 29,427,348 (1.7%).
- Net income of 62,637,482 contributed positively to equity growth.
- Dividend payments of 55,233,954 reduced retained earnings.
- Other factors increased equity by 22,023,820.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥62.64 Million | +3.6% |
| Dividends Paid | CN¥55.23 Million | -3.18% |
| Other Changes | CN¥22.02 Million | +1.27% |
| Total Change | CN¥- | 1.72% |
Book Value vs Market Value Analysis
This analysis compares Qingdao Vland Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.17x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.62x to 2.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | CN¥2.68 | CN¥15.05 | x |
| 2015-12-31 | CN¥3.00 | CN¥15.05 | x |
| 2016-12-31 | CN¥3.17 | CN¥15.05 | x |
| 2017-12-31 | CN¥3.36 | CN¥15.05 | x |
| 2018-12-31 | CN¥3.51 | CN¥15.05 | x |
| 2019-12-31 | CN¥4.44 | CN¥15.05 | x |
| 2020-12-31 | CN¥4.78 | CN¥15.05 | x |
| 2021-12-31 | CN¥6.54 | CN¥15.05 | x |
| 2022-12-31 | CN¥6.36 | CN¥15.05 | x |
| 2023-12-31 | CN¥6.77 | CN¥15.05 | x |
| 2024-12-31 | CN¥6.94 | CN¥15.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Qingdao Vland Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.74%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.72x
- Recent ROE (3.60%) is below the historical average (10.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 12.26% | 7.31% | 0.92x | 1.83x | CN¥9.81 Million |
| 2015 | 14.52% | 9.35% | 0.91x | 1.70x | CN¥21.87 Million |
| 2016 | 15.98% | 10.57% | 0.94x | 1.60x | CN¥30.90 Million |
| 2017 | 15.73% | 10.71% | 0.90x | 1.62x | CN¥31.20 Million |
| 2018 | 14.64% | 10.24% | 0.86x | 1.66x | CN¥26.42 Million |
| 2019 | 8.08% | 9.18% | 0.66x | 1.33x | CN¥-18.47 Million |
| 2020 | 10.54% | 11.35% | 0.66x | 1.40x | CN¥5.56 Million |
| 2021 | 8.26% | 11.52% | 0.52x | 1.38x | CN¥-27.88 Million |
| 2022 | 4.25% | 6.00% | 0.45x | 1.57x | CN¥-94.63 Million |
| 2023 | 4.72% | 6.73% | 0.40x | 1.78x | CN¥-90.12 Million |
| 2024 | 3.60% | 4.74% | 0.44x | 1.72x | CN¥-111.13 Million |
Industry Comparison
This section compares Qingdao Vland Biotech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $787,605,896
- Average return on equity (ROE) among peers: -14.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Qingdao Vland Biotech Co Ltd (603739) | CN¥1.90 Billion | 12.26% | 0.60x | $557.24 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $72.91 Million | -180.40% | 3.27x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $458.65 Million | 26.71% | 1.60x | $1.66 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $144.30 Million | -93.32% | 1.86x | $443.33 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $1.11 Billion | 1.01% | 0.26x | $438.41 Million |
| Chengzhi Shareholding Co Ltd (000990) | $930.16 Million | 5.16% | 0.80x | $2.24 Billion |
| Hualan Biological EngineeringInc (002007) | $588.30 Million | 13.43% | 0.39x | $3.86 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $256.72 Million | 9.82% | 0.22x | $1.19 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $170.01 Million | 48.10% | 0.80x | $5.40 Billion |
| Baolingbao Biology Co Ltd (002286) | $760.53 Million | 7.33% | 0.46x | $572.48 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $3.39 Billion | 13.95% | 0.74x | $1.90 Billion |
About Qingdao Vland Biotech Co Ltd
Qingdao Vland Biotech INC. engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally. It offers feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological … Read more